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Abstract 
 
Introduction: The increasing use of medications for smoking cessation has concerned some commentators, 
who believe that emphasizing medications for smoking cessation may lead to a belief that there are “magic 
bullets” for nicotine dependence, or alternatively that unassisted quitting is very difficult, thereby 
discouraging such quit attempts. There is little evidence on which to test these speculations. This article 
aims to address this gap by examining public understandings of nicotine addiction in order to assess the 
extent to which medical explanations of smoking have permeated public beliefs about treatments for 
smoking cessation. 
 
Methods: Interviews were conducted with a representative sample of 55 members of the Australian public 
that included smokers, ex-smokers, and nonsmokers. The data were analyzed using a standard content 
analytic method to identify recurrent themes. 
 
Results: The results revealed that although pharmacological cessation aids were the most commonly 
mentioned method for quitting, they were often recommended alongside methods such as behavioral 
strategies or counseling. Unassisted quitting was mentioned frequently, but there were mixed views on its 
effectiveness. Seeing a doctor was rarely recommended. Two common themes were that smokers had to 
“really want to quit,” and that the best treatment method would depend on the individual. 
 
Conclusions: Medical discourse of smoking cessation does not dominate public understandings of smoking 
cessation. Rather, ideas about individual choice, motivation, and willpower are emphasized 
 
 
 
 
 
Introduction 
Smoking is increasingly described and treated as a medical issue. One indicator of this is the growing 
number of smokers who use pharmacological treatments such as nicotine replacement therapy (NRT), 
varenicline, and bupropion for smoking cessation. In 2003, 32% of Australians who had made a quit 
attempt in the previous year reported using a pharmacological aid. This proportion rose to 52% in 2009 
(Cooper, Borland, 
& Yong, 2011). The use of medications for smoking cessation has also risen in the United States and the 
United Kingdom, along with increased over-the-counter availability of NRT, the marketing of 
pharmacological cessation aids by pharmaceutical companies, and government subsidies for cessation 
medications (West, DiMarino, Gitchell, & McNeill, 2005; Zhu, Lee, Zhuang, Gamst, & Wolfson, 2012). 
Associated with the growing use of medical cessation aids is the increasing role of health professionals in 
the identification and treatment of smokers (Fiore et al., 2008; Zwar et al., 2011). 
Despite evidence for the effectiveness of pharmacotherapy for smoking cessation (Cahill, Stead, & 
Lancaster, 2012; Eisenberg et al., 2008; Hughes, Stead, & Lancaster, 2010; Stead, Perera, Bullen, Mant, & 
Lancaster, 2008), some public health researchers have criticized the prominence given to pharmaceutical 
aids over unassisted cessation (Chapman & MacKenzie, 2010). These critics argue that although such 
medications increase the success rate of quit attempts in clinical trials, overall success rates are lower, with 
the majority of smokers who use NRT failing in their quit attempt (Chapman & MacKenzie, 2010). 
Moreover, evidence on the effectiveness of pharmaceutical treatments for smoking are often based on 
clinical trials sponsored by pharmaceutical companies (Chapman & MacKenzie, 2010; Etter, Burri, & 
Stapleton, 2007). Studies on the use of NRT in community samples have shown more mixed results. One 
population-based study of smokers in the United States, Canada, United Kingdom, and Australia found that 
smokers who had used pharmacological cessation aids were more likely to remain abstinent than those 
who did not use medications (Kasza et al., 2012). Other studies, however, have failed to show such 
 
benefits (Alpert, Connolly, & Biener, 2012; Walsh, 2008), raising questions about the generalizability of 
findings from clinical trials to “real world” settings. 
Chapman and MacKenzie (2010) contend that the emphasis on cessation aids such as NRT has 
overshadowed the fact that most smokers quit unaided. They argue that the pharmaceutical industry has a 
vested interest in promoting the view that quitting is difficult without medical help, thereby making 
smokers think that quitting is harder than it is. These concerns are shared by researchers in the United 
States (Pierce, Cummins, White, Humphrey, & Messer, 2012). An opposite concern has been expressed 
about the unintended consequences of increased availability and promotion of medicines for smoking 
cessation, namely, that it may lead smokers to believe that there are “magic bullets” for nicotine addiction 
that will enable them to quit easily should they choose to do so (Dingel, Karkazis, 
& Koenig, 2011). This may be of particular concern for young people, with one study suggesting that young 
people at risk of becoming smokers thought that quitting smoking would be easier after viewing ads for 
NRT and bupropion compared with ads promoting the Quitline (Wakefield & Durrant, 2006). 
A number of commentators have framed these issues as reflecting the risks of increased medicalization of 
smoking (Blum, 1984; Caron, Karkazis, Raffin, Swan, & Koenig, 2005; Chapman & MacKenzie, 2010; Dingel 
et al., 2011). Medicalization refers to the process by which issues not previously under the purview of 
medicine come to be conceptualized in terms of illness and health. Concerns about medicalization have 
typically centred on issues of power, such as the power of medical professionals to diagnose an individual 
as “healthy” or “ill” thereby creating deviant identities (Conrad, 1992). More recently, concern has centred 
on the power of “technoscientific” industries, particularly pharmaceutical corporations and biotechnology 
companies (Clarke, Shim, Mamo, Fosket, & Fishman, 2003; Moynihan, Heath, & Henry, 2002), to redefine 
behavior as illness in order to increase profits. 
Finally, these critics argue that medicalizing smoking may overemphasize the treatment of smokers, and 
overlook the well-documented social influences on smoking uptake and maintenance. For example, 
developments in pharmacogenetics, which involve tailoring treatments for smoking cessation based on the 
results of individual genetic tests, may reduce support and funding for population-wide tobacco control 
strategies that have proven effective in reducing smoking prevalence (Caron et al., 2005; Gartner, Carter, & 
Partridge, 2012). 
These claims about the potential adverse impacts of medicalization on individual beliefs and smoking 
behavior are not typically based on empirical research. There is little research examining the extent to 
which medical views of smoking have penetrated the understandings of the public in general and smokers 
in particular. Survey data suggest that there is considerable public ambivalence about the idea that 
smoking is a medical problem. For example, both the general public and smokers tend not to support the 
view that smoking is caused by biological factors and are more likely to endorse the idea that smoking is a 
habit (Cunningham, Sobell, Freedman, & Sobell, 1994; Hughes, 2009). Qualitative and quantitative 
research have demonstrated some resistance to treating smoking as a medical issue, with many smokers 
emphasizing the importance of willpower and expressing a belief that using medication to quit smoking is 
sign of weakness (Balmford & Borland, 2008; Carter, Borland, & Chapman, 2001). 
Public health researchers have acknowledged the importance of understanding how lay concepts of 
health, illness, and treatment may affect health behavior (Kuppin & Carpiano, 2006; Popay & Williams, 
1996). In light of the increasing use and promotion of medications for smoking cessation, there is a need 
for research exploring lay attitudes toward smoking cessation and the role that drug treatments play in it. 
This article outlines findings from qualitative research undertaken with a cross section of the Australian 
population that included smokers, ex-smokers, and nonsmokers and explored participants’ views about 
treatments for nicotine addiction. Although the views of nonsmokers are rarely solicited in smoking 
research, they are important to explore because research shows that the attitudes of nonsmoking family 
and friends toward smoking can influence the motivation of smokers to quit (Australian Institute of Health 
and Welfare, 2011; Fiore et al., 2008; Patten et al., 2011). This study aims to explore the opinions that the 
public hold on the role of treatments in smoking cessation, examine the extent to which medical 
explanations of smoking have affected the understandings of the public, and describe alternative 
conceptualizations of smoking that may influence attitudes in relation to treatment options for nicotine 
addiction. 
 
 
 
 
Methods 
 
The data analyzed in this article were drawn from a study exploring public understandings of addiction. 
Findings about the ways in which the public describe the causes of addiction, and their ideas about the 
brain disease model of addiction have been published elsewhere (Meurk, Carter, Hall, & Lucke, 2013). The 
study involved face-to-face semi-structured interviews with 55 participants, exploring their ideas about 
addiction to heroin, alcohol, and nicotine. A market research company was contracted to recruit the 
participants and conduct the interviews using an interview schedule designed by the researchers. 
Potential participants were selected from a representative database of Australian households developed 
by Roy Morgan Research. Households from the database located in the Greater Brisbane area were 
randomly selected. Once households were selected, the youngest male aged more than 14 years (or if not 
available, the youngest female aged more than 14 years) was asked to participate. This approach increased 
the representativeness of the sample of young people, particularly young males who are the hardest to 
recruit. Quota sampling was used to ensure that the sample was age and gender representative (Table 1). 
Semi-structured qualitative interviews, followed by a brief quantitative survey, were conducted with 
willing participants at a location of their choice. All participants received a gift voucher in appreciation for 
their time. The findings in this article were drawn from participants’ responses to the question, “What do 
you think is the best way to treat someone who is addicted to nicotine, and why?” 
Of the 55 participants, 14 reported being current smokers (10 were daily smokers, 2 weekly smokers, and 2 
less than weekly smokers), and 40 were nonsmokers at the time of the interview. One participant did not 
answer this question. Of the 40 nonsmokers, 11 reported being ex-smokers. 
 
Data Analysis 
 
Interviews were transcribed and imported into qualitative research software Nvivo 9 (QSR International 
Pty Ltd., 2010). 
Each treatment method mentioned by a participant was coded as a category. In addition, thematic data 
analysis was used in order to identify recurrent themes across treatment methods. Categories were 
verified by an iterative process that involved reading each interview in light of the categories developed, 
and amending or adding categories as required. Each participant quoted is referred to by their age, sex, 
and whether they are a current smoker, an ex-smoker, or have never smoked. 
 
 
Results 
 
The most commonly mentioned treatment for smoking cessation was the use of pharmacological cessation 
aids (n = 30). Although not strictly a “treatment,” unassisted quitting was the next most frequently 
described strategy for quitting (n = 24). The use of behavioral strategies (n = 10) and counseling (n = 7) 
were also discussed relatively frequently although not as often as pharmacological cessation aids or 
unassisted quitting. An important observation was that participants often recommended a number of 
treatment strategies, as outlined below. 
 
Pharmacological Cessation Aids 
 
When asked what they thought was the best treatment for nicotine addiction, participants most often 
mentioned pharmacological cessation aids, mainly in the form of NRT patches. This, no doubt, reflects the 
fact that NRT is the most widely used pharmacological cessation aid in Australia (Cooper et al., 2011), and 
the only pharmacological cessation aid that can be advertised directly to consumers. It was less common 
for participants to mention prescription medications and those that did often referred to “tablets.” Very 
few participants mentioned a specific prescription medication. This suggests that most Australians have 
only a vague knowledge of cessation medications, which is not surprising given that they are not allowed 
 
to be advertised directly to consumers in this country. 
 
Although a few participants mentioned pharmacological methods as a sole treatment for nicotine 
addiction, it was more common for pharmacological cessation aids to be discussed alongside behavioral 
strategies, counseling, and hypnotherapy. The following quote was typical: 
 
Well the nicotine patches are quite good. There’s a couple of medications that are used that are 
quite good. Having a plan; having a friend doing it with you helps. And often you can make a plan 
of when you’re going to stop, whether you’re going to use patches. (male, 50–59, never smoked) 
 
The belief that medications were useful did not necessarily displace the importance of alternative 
methods, such as counseling: 
 
Well obviously these alternatives — nicotine patches and all that—are successful to a great 
degree. But I think there’s a need for counseling in that regard too. Why are you smoking? Let’s get 
to the bottom of it, et cetera. (male, 70 or over, never smoked) 
 
Patches were seen as effective, but insufficient because they did not address the underlying reasons why 
someone smoked. Another common theme was that different methods would work for different people. 
Again, pharmacological cessation aids were situated as one method among others: 
 
I think that depends on the person a lot of times. With the things that I’ve seen, sometimes 
hypnosis works, you know, sometimes those tablets that they take work. That book by that guy 
Carr, or whatever, that I gave my brother because he couldn’t give up, that worked for him. Yeah, I 
think it depends on the person. (female, 40–49, never smoked) 
 
Both smoking and nonsmoking participants commented that “really” wanting to quit was a prerequisite for 
successful quitting, regardless of whether pharmacological cessation aids were used or not: 
 
I think there are some medicines, some type of tablets or something, people have — somebody 
taking that tablets you don’t feel is — you want to smoke or something, but the rest is on the 
people. Like me, if I want to quit I should quit, should say to myself that’s okay, it’s enough, I want 
to quit. So that’s up to the people, if they want really want to quit, they would quit. (male, 25–29, 
current smoker) 
 
This approach portrayed individual decision making, motivation, and willpower as the key factors in 
successful quitting, not medical assistance. For example, one smoker, after an unsuccessful attempt using 
patches, developed a side effect from prescription medication. However, she blamed her lack of success on 
a deficiency in willpower, rather than any limitations of the medication: 
 
Yeah, no that didn’t help — and I had some pills I got from the doctor and they just — I just came 
out in boils everywhere — they were no good. It’s just willpower, I got no willpower. (female, 50–
59, current smoker) 
 
Another smoker who had been given prescription medication by their doctor was reluctant to use it for 
fear of side effects. She expressed a preference for quitting unaided: 
 
Yes well there’s quick — there’s a lot of different things you can do. And as I said I’ve got tablets 
but I’m reluctant to take them. But hopefully I’ll be able to do what I did before and just stop. But I 
can’t answer that. I hope I do for my own sake. (female, 60–69, current smoker) 
 
This ambivalence toward cessation aids was not expressed by all smokers. One long-time smoker 
expressed a fear of quitting, but seemed to gain encouragement from the availability of cessation aids: 
 
 
Well for me I’m sort of — I want to give it up but I’m scared to because I’ve smoked all my life. So 
it’s also a fear factor there — I know I couldn’t give it up cold turkey but with those Nicorette’s and 
all this sort of stuff — no I’m going to give it up. (male, 49–49, current smoker) 
 
Unassisted Quitting 
 
In asking participants about the best “treatment” for nicotine addiction, there was the potential to bias 
responses toward medical or psychological interventions. Nonetheless, participants still referred to 
unassisted quitting, which was often positioned as the ideal method for smoking cessation. The use of 
cessation aids was sometimes described as a secondary option, to be used only where unassisted quitting 
had been unsuccessful: 
 
I mean maybe you try what my husband did, the cold turkey, and if that doesn’t work you try the 
patches or whatever. (female, 60–69, never smoked) 
 
After you’ve made that decision, be consistent, follow through with it, persist. And — well of 
course some people might need medical additional help, patches but personally I never had that 
problem so I can’t empathise with — put myself in their place but I believe it’s best to just drop it 
instead of just slowly trying to. (male, 60–69, never smoked) 
 
Participants often talked about how difficult or easy it would be to quit unassisted. Respondents were 
divided on this point. Some believed that quitting unassisted would be very difficult and that only strong-
willed people would be able to stop smoking this way: 
 
My parents just stopped like that and I always find that incredibly impressive when people do that. 
So I can appreciate it can be done but at the same time I do appreciate that it is very hard and 
some people will try over and over again before they finally make it. (female, 40–49, never 
smoked) 
 
This fitted with the idea that different methods work for different people. Quitting cold turkey was often 
described as a method suitable only for some people, typically those with willpower or “strong minds”: 
 
Yeah, there’s a lot of help out there and I have seen people with strong minds just stop, even 
though it’s hard. But there’s other people that need more help. (female, 40–49, never smoked) 
 
Others expressed the belief that unassisted quitting would be the easiest way to quit. These views were 
often expressed by those who saw smoking as a habit that smokers can and should “just stop”: 
 
I just think nicotine is probably a mental thing, not so much as your body probably needs it. I just 
think it’smore like a habit. You just walk downstairs; have a coffee and a cigarette. Whereas walk 
downstairs, have a coffee and have a chocolate bar instead or something and then do that for five 
days in a row and you’ll probably be cured from wanting to smoke anymore. (female, 25–29, never 
smoked) 
 
The above quote illustrates the way in which an individual’s explanatory model of nicotine addiction 
influenced a participant’s views about the most appropriate way to quit. Understanding smoking as a 
habit, rather than a physiological dependency, led this participant to see quitting as a matter of replacing 
one habit with another. A small number of those who saw smoking as a habit rejected the idea that 
smokers needed any treatment for nicotine addiction because they did not believe that nicotine was as 
addictive as claimed: 
 
I actually don’t think they’re really addicted to tell you the truth. I don’t think nicotine is as an 
 
addictive drug as everybody makes out. (male, 50–59, ex-smoker) 
 
The concept of motivation and the importance of personal decision making were again emphasized in 
discussions around unassisted quitting: 
 
He has to help himself. He wants to do it. Throw it away, don’t just go through the stages, just 
throw it away, make a decision, publicise it, tell everybody that counts. (male, 60–69, never 
smoked)  
 
Best way to treat them is you can’t treat them. It’s up to them whether they want to give up or 
not. You’re not going to force anyone to do anything that they don’t want to. (male, 40–49, ex-
smoker) 
 
 
Behavioral Strategies 
 
The use of behavioral strategies was also mentioned often as a treatment option for nicotine addiction. 
The strategies described under this heading included reducing the intake of cigarettes, replacing smoking 
with another behavior, recruiting social support for abstinence, and avoiding environments where smokers 
were exposed to tobacco smoke or other smoking-related cues: 
 
You just need to take them out of the environment, so that they — well, take them out of the 
environment and even into a neutral environment where there’s no need for temptation and 
something that won’t — teach them not to be drawn to it kind of thing. (female, 18–24, never 
smoked) 
 
I don’t know, hey. I reckon to — because my dad was addicted. The way — how he got off smoking 
was to keep himself busy and not just sit around. So he just keeps himself busy every day, every 
day. And chew a bubble-gum. [Laughs]. Chew a bubble-gum, ‘cause that will keep your mind off 
smoking. (female, 18–24, current smoker) 
 
 
Counseling 
 
Counseling was one of the most commonly discussed methods for treating nicotine addiction. Generally, a 
less intensive form of counseling was thought to be required for smokers than for those addicted to 
alcohol or heroin. 
 
Well nicotine is not really — I mean, someone who takes nicotine’s not completely — just — they 
can be a functioning member of society. So you don’t need a rehab, but possibly a counseling or 
somebody to help like a motivational coach, or something like that. (male, 18–24, current smoker). 
 
Seeing a Doctor 
 
Seeing a doctor was rarely mentioned by participants, with only one participant describing doctors as 
having a supervisory role in relation to smoking. Several participants described the cost of seeing a doctor 
and the cost of medications for smoking cessation as a barrier to seeking medical assistance for smoking. 
 
 
Discussion 
 
These results suggest that although the medicalization of smoking cessation has occurred to a degree, the 
process is far from complete. Pharmacological cessation aids were the most frequently mentioned 
 
treatment for smoking cessation, but unassisted quitting was often described as the ideal method. 
Participants often recommended that medications only be used when unassisted quitting had been 
unsuccessful. Even then they often articulated that behavioral methods that dealt with the social and 
emotional aspects of smoking, for example, counseling, were also desirable to reduce relapse. The finding 
that the public ascribe prominence to unassisted quitting is strengthened by the fact that the wording of 
the question, in which respondents were asked what they thought was the best “treatment” for nicotine 
addiction, may have biased their answers toward medical options. 
There was also little evidence that medications for smoking cessation were perceived as “magic bullets.” 
Doctors were rarely mentioned in relation to smoking cessation, perhaps reflecting the market dominance 
of NRT, which is available over the counter and so does not require a doctor’s visit. It may also partially 
reflect the commonly held belief that smoking is a habit, or at the least a much less serious addiction than 
other drug addictions, and hence that smokers are not in need of medical assistance. 
It is clear that the Australian public has not uncritically accepted the idea that smoking requires medical 
treatment. Early theorizing about medicalization described it as a oneway process, with the public 
portrayed as passive instruments of institutional power (Ballard & Elston, 2005). However, more recent 
research has emphasized the active ways in which people respond to this process, including the ways in 
which the public resists medical discourse (Ballard & Elston, 2005). The results of this study are more 
supportive of the latter view in revealing some resistance to the medicalization of smoking. Only a small 
number of participants believed that nicotine was not as addictive as commonly thought and that smokers 
should “just stop.” But the idea that smoking is a habit remained a common theme in public discourse 
about smoking that has not been purged from the public lexicon, as was advocated in the first issue of the 
journal Tobacco Control (Davis, 1992). 
The tobacco industry has promoted the idea that “habit” and “addiction” are mutually exclusive terms 
(Davis, 1992), but smokers appear willing to accept both of these explanations of smoking (Hughes, 2009). 
The results suggest that ideas about the biological bases of smoking have not displaced the idea that 
smoking is a habit. This may explain why participants in this study often recommended cessation 
medications and behavioral strategies or counseling. 
The belief that smokers have to “really want to quit” to be successful was a commonly expressed belief in 
this study as it has been in others (Balmford & Borland, 2008; Carter et al., 2001). This belief was expressed 
by smokers, nonsmokers, and ex-smokers. Balmford and Borland (2008) note that this belief may 
discourage quit attempts if individuals believe that it will be fruitless unless they feel no ambivalence about 
smoking and are “ready” to give up, a point that many smokers may never reach. Another important idea 
about smoking cessation expressed by participants was that the best treatment “depends on the 
individual.” What works for one smoker will not necessarily work for another. This view of nicotine 
addiction implies that smokers may need to try a number of methods in order to find one that suits them. 
Pharmacological cessation aids are positioned within this discourse as one method among others. Given 
that these two ideas circulate widely in public discourse, it is likely that smokers are frequently exposed to 
them. Further research should be conducted exploring the potential behavioral consequences of the 
commonly held beliefs that smokers must “really want” to quit to be successful and that the best method 
for quitting depends on the individual. In addition, attention should be given to the implications for how 
clinicians should deal with smokers who express these views. 
This study examined the views of the general public about treatments for smoking cessation. This is 
important given that smokers do not make decisions in isolation, but are influenced by their social 
environment, including family, friends, and messages in the media. Although some smokers were part of 
this sample, their recruitment was incidental. Further qualitative research specifically targeting smokers 
and exploring their attitudes toward medications for smoking cessation would complement this research. 
It is important that qualitative research about smoking continues to be conducted in order to capture the 
complexity of public beliefs around smoking and quitting. It is also important that this research be 
conducted at multiple timepoints in order to explore changes in public discourse about smoking in the face 
of new treatment developments and continued promotion and increased availability of medical aids for 
smoking cessation. 
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